公开(公告)号：US20030129230A1

公开(公告)日：2003-07-10

申请号：US10189932

申请日：2002-07-03

申请人： Penwest Pharmaceuticals Company

发明人： Anand R. Baichwal ,  Huai-Hung Kao ,  Troy W. McCall

IPC分类号： A61K009/22 ,  A61K031/485

CPC分类号： A61K31/485 ,  A61K9/2018 ,  A61K9/205 ,  A61K9/2054

摘要： Sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.

摘要翻译： 羟吗啡酮或其药学上可接受的盐的缓释制剂; 制备羟吗啡酮缓释制剂或其药学上可接受的盐的方法; 提供了使用羟吗啡酮的缓释制剂或其药学上可接受的盐来治疗患有疼痛的患者的方法。

公开(公告)号：US20030104057A1

公开(公告)日：2003-06-05

申请号：US10215141

申请日：2002-08-08

发明人： Yihong Qiu ,  J. Daniel Bollinger ,  Sandeep Dutta ,  Howard S. Cheskin ,  Kevin R. Engh ,  Richard P. Poska

IPC分类号： A61K031/19 ,  A61K009/22

CPC分类号： A61K31/191 ,  A61K9/2009 ,  A61K9/2018 ,  A61K9/2054 ,  A61K31/19

摘要： A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.

公开(公告)号：US20030104056A1

公开(公告)日：2003-06-05

申请号：US10211729

申请日：2002-08-02

发明人： Edward M. Rudnic ,  James D. Isbister ,  Donald J. Treacy JR. ,  Sandra E. Wassink

IPC分类号： A61K009/22

CPC分类号： A61K9/2054 ,  A61K9/1652 ,  A61K9/2031 ,  A61K9/2081 ,  A61K9/5015 ,  A61K9/5026 ,  A61K9/5047 ,  A61K9/5084 ,  A61K31/7048

摘要： An anti-viral product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the anti-viral product being reached in less than about twelve hours after initial release of anti-viral from the product.

摘要翻译： 抗病毒产品由至少三种延迟释放剂量形式组成，每种缓释剂型具有不同的释放特征，抗原病毒产物的C max在抗病毒初次释放后少于约十二小时内达到 该产品。

公开(公告)号：US20030100611A1

公开(公告)日：2003-05-29

申请号：US10280309

申请日：2003-01-22

发明人： Bret Berner ,  Sui Yuen Eddie Hou ,  Gloria M. Gusler

IPC分类号： A61K031/198 ,  A61K009/22

CPC分类号： A61K9/0065 ,  A61K9/0002 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/48 ,  A61K31/195 ,  A61K31/197 ,  A61K45/06

摘要： A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.

公开(公告)号：US20030099705A1

公开(公告)日：2003-05-29

申请号：US10259143

申请日：2002-09-27

申请人： CV Therapeutics, Inc.

发明人： Andrew A. Wolff ,  Fiona Baker ,  John Richard Langridge

IPC分类号： A61K009/20 ,  A61K009/22 ,  A61K031/495

CPC分类号： A61K9/2846 ,  A61K9/2027 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/2866 ,  A61K31/495 ,  A61K31/496 ,  Y10S514/964

摘要： A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.

公开(公告)号：US20030097120A1

公开(公告)日：2003-05-22

申请号：US10162084

申请日：2002-06-05

发明人： Paul J. Santerre

IPC分类号： A61K009/22

CPC分类号： C08G18/6446 ,  A61L33/0017 ,  C08G18/2805 ,  C08G18/2885 ,  C08G18/44 ,  C08G18/4854 ,  C08G18/6484 ,  C08G18/771 ,  C08G65/007

摘要： This invention relates to macromolecule modifiers containing biologically active drugs/biomolecules, or precursors thereof, and fluoroligomers; compositions comprising the macromolecules containing the drugs and fluoroligomers in admixture with polymers, particularly biomedical polymers; articles made from the admixtures, particularly medical devices. Specifically, the modifier has the general formula 1 comprising an oligomeric polymeric segment having a theoretical molecular weight of less than 15,000, and being compatible with said base polymer; wherein nulloligonull is a first oligomeric segment; nulllink Anull is a second coupling segment linking one nulloligonull to another nulloligonull within said central portion; n is 0 to 20; nullfluoronull is a polyfluoro oligomeric group; and nulllink Bnull is a first coupling segment linking said central portion to said nullfluoronull through said first coupling segment; and coupled to a bioactive moiety nullBionull or precursor thereof; and m is 1 to 20.

摘要翻译： 本发明涉及含有生物活性药物/生物分子或其前体和氟低聚物的大分子改性剂; 包含含有药物的大分子和与聚合物特别是生物医学聚合物混合的氟低聚物的组合物; 由外加剂制成的物品，特别是医疗器械。 具体而言，改性剂具有通式，其包含理论分子量小于15,000的低聚物聚合物链段，并与所述基础聚合物相容; 其中[oligo]是第一低聚片段; [链接A]是将所述中心部分中的一个[oligo]与另一个[oligo]连接的第二耦合部分; n为0〜20; 氟是多氟低聚基团; 并且[link B]是通过所述第一耦合段将所述中心部分连接到所述[氟]的第一耦合段; 并与生物活性部分[Bio]或其前体偶联; m为1〜20。

公开(公告)号：US20030091632A1

公开(公告)日：2003-05-15

申请号：US10222959

申请日：2002-08-16

申请人： Neurocrine Biosciences, Inc.

发明人： D. Bruce Campbell ,  W. Jay Thiele

IPC分类号： A61K009/22

CPC分类号： A61K9/4808 ,  A61K9/2081 ,  A61K9/209 ,  A61K9/5084 ,  A61K31/519

摘要： Controlled-release formulations providing a nullpulsednull plasma profile of a sedative-hypnotic compounds having a particularly short half-life are provided. The formulation contains a sedative-hypnotic compound or precursor thereof that is metabolized to generate a sedative-hypnotic compound in vivo, wherein the compound has a mean plasma half life ranging from 0.1 to 2 hours; and at least one release retardant such that, following administration of the formulation to a patient, the patient has specified pulsed plasma profile for the sedative-hypnotic compound as disclosed herein. In a preferred embodiment, the sedative-hypnotic compound is NBI-34060.

摘要翻译： 提供了提供具有特别短的半衰期的镇静催眠化合物的“脉冲”血浆曲线的控制释放制剂。 制剂含有镇静催眠化合物或其前体，其体内代谢产生镇静催眠化合物，其中该化合物的平均血浆半衰期为0.1至2小时; 和至少一种释放阻滞剂，使得在向患者施用制剂后，患者已经指定了本文公开的镇静催眠化合物的脉冲血浆谱。 在优选的实施方案中，镇静催眠化合物是NBI-34060。

公开(公告)号：US20030083645A1

公开(公告)日：2003-05-01

申请号：US10238844

申请日：2002-09-09

申请人： Massachusetts Institute of Technology

发明人： Aimee B. Angel ,  Ian W. Hunter

IPC分类号： A61K009/22

CPC分类号： A61M37/0015 ,  A61M5/14244 ,  A61M5/14248 ,  A61M5/155 ,  A61M5/1723 ,  A61M5/425 ,  A61M5/46 ,  A61M2005/1405 ,  A61M2005/14204 ,  A61M2005/14252 ,  A61M2005/14268 ,  A61M2005/1581 ,  A61M2037/0007 ,  A61M2037/0023 ,  A61M2037/003 ,  A61M2037/0038 ,  A61M2205/0266 ,  A61M2205/50 ,  A61M2205/8206 ,  A61M2230/65

摘要： A transdermal transport device includes a reservoir for holding a formulation of an active principle, and an array of needles which have bores in fluid communication with the reservoir to facilitate transporting the formulation to and from the reservoir through the needles. The device also includes a first actuator which drives the array of needles into the body, and a second actuator which pumps the formulation between the reservoir and the body through the needles. The first actuator is reversible to withdraw the needles from the body.

摘要翻译： 透皮运输装置包括用于保持活性成分的制剂的储存器和具有与储存器流体连通的孔的针阵列，以便于通过针将制剂运送到储存器和从储存器传送。 该装置还包括将针阵列驱动到主体中的第一致动器，以及通过针将储存器和身体之间的配制物泵送的第二致动器。 第一个致动器是可逆的，以从身体中抽出针头。

公开(公告)号：US20030077323A1

公开(公告)日：2003-04-24

申请号：US10093321

申请日：2002-03-07

发明人： Edward M. Rudnic ,  James D. Isbister ,  Donald J. Treacy JR. ,  Sandra E. Wassink

IPC分类号： A61K009/22 ,  A61K031/7048 ,  A61K031/43

CPC分类号： A61K9/5084 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/5026 ,  A61K9/5047 ,  A61K31/65 ,  A61K45/06 ,  A61K2300/00

摘要： An antibiotic product for delivering at least Amoxicillin or Clarithromycin that is comprised of three dosage forms with different release profiles with each of Amoxicillin and Clarithromycin being present in at least one of the dosage forms.

摘要翻译： 用于递送至少阿莫西林或克拉霉素的抗生素产品，其由具有不同释放曲线的三种剂型组成，每种阿莫西林和克拉霉素存在于至少一种剂型中。

公开(公告)号：US20030068374A1

公开(公告)日：2003-04-10

申请号：US10204185

申请日：2002-08-19

发明人： Shigeru Kamei ,  Mami Ojima ,  Takahito Kitayoshi ,  Yasutaka Igari

IPC分类号： A61K009/22

CPC分类号： A61K31/4184 ,  A61K9/1611 ,  A61K9/1647 ,  A61K31/00

摘要： A sustained-release preparation containing a physiologically active compound slightly soluble in water, a component obtained by treating with water a polyvalent metal compound slightly soluble in water, and a biodegradable polymer which are improved in the release-control and stabilization of the physiologically active compound slightly soluble in water and can be produced by a process suitable for mass production.

摘要翻译： 一种含有微溶于水的生理活性化合物的缓释制剂，通过用水处理微溶于水的多价金属化合物获得的成分和生物降解性聚合物，其改善了生理活性化合物的释放控制和稳定性 微溶于水，可通过适合批量生产的方法生产。